Serina Therapeutics (SER) AI Stock Analysis

• Market Cap: $54.53M
• Dividend Yield: N/A
• Average Volume (3M): 225.34K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.73
• Revenue Growth: 34.04%
• EPS Growth: 55.34%
• Country: US
• Employees: 12
• Sector: Healthcare
• Sector Strength: 51
• Industry: Biotechnology
• EPS (TTM): -0.66
• Shares Outstanding: 10,250,588
• 10 Day Avg. Volume: 624,558
• 30 Day Avg. Volume: 225,336
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.11
• Enterprise Value/Revenue: 467.15
• Enterprise Value/Gross Profit: 30.36K
• Enterprise Value/Ebitda: -4.87
• 1Y Price Target: $15.00
• Price Target Upside: 181.95% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 41 Neutral
• Price Target: $5.00 ▼(-6.02% Downside)

Serina Therapeutics faces significant financial and technical challenges, with severe inefficiencies and a bearish market trend. The negative P/E ratio and lack of dividend yield further highlight valuation concerns. While the advancement of SER-270 is a positive step, it does not sufficiently mitigate the overall risks.

Positive Factors

International Expansion

SER-252 delivery system receives market authorization in Brazil, indicating growing international recognition and potential for SER-252.

Market Opportunities

Market metrics appear extremely attractive with existing apomorphine drug/device combination products priced high, providing benchmarks for SER-252 pricing if approved.

Regulatory Approval

Regulatory clearance obtained for SER-252 clinical development pathway in Parkinson's disease.

Negative Factors

Clinical Trials

SER is expecting to dose the first patient in the Phase Ib trial of SER-252 in advanced Parkinson's Disease in 4Q25 following the planned IND.

Competition

The broadening approval footprint of enFuse bodes well for global acceptance of SER-252 in the coming years.

Existing Treatments

Current formulations of apomorphine (APOKIN and ONAPGO, both marketed by Supernus Pharmaceuticals) have severe adverse events, which can hinder treatment compliance.

Serina Therapeutics Business Overview & Revenue Model

Company Description

Serina Therapeutics (SER) is a biotechnology company focused on developing innovative therapies for unmet medical needs, particularly in the fields of oncology and autoimmune disorders. The company specializes in creating novel drug delivery systems and formulations that enhance the efficacy and safety of existing therapies. With a strong emphasis on research and development, Serina Therapeutics aims to improve patient outcomes through its proprietary technologies and a pipeline of therapeutics.

How the Company Makes Money

Serina Therapeutics generates revenue primarily through strategic partnerships and collaborations with pharmaceutical companies that seek to utilize its proprietary drug delivery technologies. The company may also earn income from licensing agreements for its developed products, as well as potential milestone payments and royalties from partnered drug development programs. Additionally, government grants and funding for research projects may contribute to the company's financial resources, allowing it to advance its product pipeline and expand its therapeutic offerings.

Serina Therapeutics Financial Statement Overview

Summary

Serina Therapeutics is facing severe financial challenges across all key financial statements. The income statement reflects substantial losses and declining revenue, the balance sheet is under strain due to high liabilities and negative equity, and cash flow issues point to operational inefficiencies. These factors collectively suggest a need for strategic restructuring or significant operational improvements to ensure future viability.

Income Statement

Serina Therapeutics has experienced significant volatility in revenue and profitability. The TTM data shows a drastic decline in revenue, leading to negative gross and net profit margins. This indicates severe inefficiencies and a struggle to generate sufficient income. Previous periods also reflect a trend of high losses, with EBIT and EBITDA margins persistently underperforming.

Balance Sheet

The balance sheet shows a concerning financial structure with a very low equity base and high liabilities, resulting in a negative equity in some periods. The debt-to-equity ratio is not ideal, and the return on equity is not calculable due to negative equity. This suggests high financial risk and instability.

Cash Flow

The cash flow statement highlights consistent negative free cash flow, indicating operational challenges. The operating cash flow is significantly negative, suggesting that the company struggles to generate cash from its core activities. Despite some positive financing activities, the overall cash flow position is weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	130.00K	56.00K	3.15M	500.00K	3.04M	54.00K
Gross Profit	2.00K	-138.00K	3.06M	355.00K	-110.00K	-1.23M
EBITDA	-12.47M	-10.49M	5.92M	-7.05M	-7.35M	-8.74M
Net Income	-12.59M	-11.14M	5.27M	-2.68M	-1.26M	-10.87M
Balance Sheet
Total Assets	8.94M	6.72M	11.96M	858.04K	1.84M	3.92M
Cash, Cash Equivalents and Short-Term Investments	6.04M	3.67M	7.62M	532.23K	1.31M	527.00K
Total Debt	185.00K	268.00K	4.37M	1.81M	398.17K	6.30M
Total Liabilities	7.29M	6.22M	6.61M	38.64M	36.95M	9.32M
Stockholders Equity	1.80M	641.00K	5.47M	-17.21M	-11.83M	-5.12M
Cash Flow
Free Cash Flow	-15.63M	-17.16M	-2.98M	-2.09M	-2.36M	-7.84M
Operating Cash Flow	-15.62M	-17.14M	-2.48M	-2.08M	-2.25M	-7.82M
Investing Cash Flow	-54.00K	-22.00K	-504.00K	980.94K	823.32K	-20.00K
Financing Cash Flow	15.60M	13.21M	10.07M	1.31M	1.08M	5.96M

Serina Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 5.32
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SER, the sentiment is Neutral. The current price of 5.32 is below the 20-day moving average (MA) of 5.32, below the 50-day MA of 5.51, and above the 200-day MA of 5.25, indicating a neutral trend. The MACD of -0.06 indicates Positive momentum. The RSI at 48.72 is Neutral, neither overbought nor oversold. The STOCH value of 13.60 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SER.

Serina Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.26	-41.41%	2.22%	22.87%	-2.01%
KRON	51 Neutral		―		―	21.15%	46.44%
PDSB	50 Neutral	$57.83M	―	-156.16%	―	―	25.26%
VRCA	46 Neutral	$52.85M	―	-1546.58%	―	5.72%	55.79%
GANX	46 Neutral	$71.54M	―	-240.21%	―	―	49.82%
SER	41 Neutral	$54.53M	―	45.59%	―	34.04%	55.34%
STRO	40 Neutral	$72.66M	―	-347.64%	―	-38.31%	-36.91%

Serina Therapeutics Corporate Events

Serina Therapeutics Amends Bylaws for Governance Transparency

On August 18, 2025, Serina Therapeutics‘ Board of Directors amended the company’s bylaws to introduce safe harbor procedures for transactions involving directors, officers, and controlling stockholders with potential conflicts of interest. Additionally, the amendment expanded the forum selection clause to cover stockholder claims related to the corporation’s business, conduct, or rights, potentially impacting how legal disputes are managed and enhancing corporate governance transparency.

Serina Therapeutics Advances SER-270 for Tardive Dyskinesia

On July 29, 2025, Serina Therapeutics announced the advancement of its drug candidate, SER-270, a VMAT2 inhibitor for tardive dyskinesia, coinciding with CEO Steve Ledger’s presentation at the BTIG Virtual Biotechnology Conference. This development highlights Serina’s strategic focus on innovative treatments for neurological conditions, potentially enhancing its market position and offering new therapeutic options for stakeholders.

Serina Therapeutics Announces 2025 Annual Meeting Date

Serina Therapeutics announced that its 2025 annual meeting of stockholders will be held on November 7, 2025. The change in the meeting date from the previous year affects the deadline for stockholder proposals, which is set for August 15, 2025. This adjustment provides stakeholders with a new timeline for submitting proposals and nominations, ensuring compliance with regulatory requirements and the company’s bylaws.